ArticleInternational journal of general medicine2026
Apical-Predominant Myocardial Fibrosis in Hypertensive Heart Disease Revealed by CMR Feature Tracking and T1 Mapping.
Article in International journal of general medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To evaluate the utility of cardiac magnetic resonance feature tracking (CMR-FT) and T1 mapping in quantifying myocardial injury in early hypertensive heart disease, focusing on segmental parameter differences. Methods: A total of 156 hypertensive patients were enrolled and divided into a left ventricular hypertrophy (LVH) group (n=63) and a non-hypertrophy (Non-LVH) group (n=93) based on the left ventricular mass index (LVMI). All patients underwent CMR examination. Left ventricular function, myocardial strain, global and segmental native T1 values, and extracellular volume (ECV) were obtained using post-processing software. Parameters were compared between the two groups, with special attention to differences among myocardial segments to identify regional characteristics of fibrosis distribution. Results: Compared with the Non-LVH group, the LVH group showed significantly lower absolute values of global longitudinal strain (GLS; median: -10.80% vs -15.75%), global circumferential strain (GCS), and global radial strain (GRS) (all P <0.05), while global native T1 (median: 1080 ms vs 1036 ms) and ECV (median: 29.8% vs 27.0%) were significantly elevated (P <0.05). Notably, myocardial fibrosis exhibited an apical-predominant distribution pattern, with the most significant parameter differences observed in the apical segments. For instance, in the LVH group, ECV in the apical septal segment (segment 14) was significantly higher [33.50% (30.40, 36.15) vs 26.70% (26.70, 27.90) in Non-LVH, P=0.001], and native T1 in the apical anterior segment (segment 13) was elevated [1105.65 ± 72.31 ms vs 1039.80 ± 47.77 ms, P=0.006], suggesting a possible apical-predominant pattern of myocardial fibrosis.These changes correlated with high diagnostic accuracy for LVH: GLS showed the highest AUC (0.91) in ROC analysis. In the LVH group, global ECV positively correlated with native T1 and LGE positivity, and negatively with GCS and GLS (P <0.05). Conclusion: CMR-FT and T1 Mapping techniques can effectively and quantitatively assess myocardial injury and fibrosis in hypertensive patients. Global longitudinal strain (GLS) is a sensitive parameter for diagnosing left ventricular hypertrophy (LVH), and myocardial fibrosis in patients with hypertension-induced LVH exhibits an apical-predominant distribution pattern.This spatial pattern, if validated prospectively, could serve as a potential imaging biomarker for monitoring in hypertensive patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.